HDFC Bank Limited Common Stock vs Summit Therapeutics Inc — how do they compare? HDFC Bank Limited Common Stock trades at $22.27 (market cap $110.31B), while Summit Therapeutics Inc trades at $17.4 (market cap $13.71B). The key difference: HDFC Bank Limited Common Stock is far larger — about 8× Summit Therapeutics Inc's market cap, and HDFC Bank Limited Common Stock pays a 1.86% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 1 Days and Summit Therapeutics Inc for 16 Days on average.
| HDB | SMMT | |
|---|---|---|
Market Cap | $110.31B | $13.71B |
Volume | 13,548,204 | 6,173,057 |
Sector | Financials | Health |
52-Week High | $37.18 | $26.38 |
52-Week Low | $21.84 | $12.43 |
Typical Hold Time | 1 Days | 16 Days |
Enterprise Value | $14.19T | $13.04B |
Dividend Yield | 1.86% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Trailing returns across standard periods
Latest headlines on both assets
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →